ARIDIS PHARMACEUTICALS INC (ARDS) Stock Price, Quote, News and Overview
NASDAQ:ARDS - Nasdaq - US0403341045 - Common Stock - Currency: USD
ARDS Quote, Performance and Key Statistics
0.3101
+0.05 (+17.91%)
The current stock price of ARDS is 0.3101 USD. In the past month the price increased by 22.81%. In the past year, price decreased by -72.31%.
ARDS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ARDS
Company Profile
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company is headquartered in Los Gatos, California and currently employs 37 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The firm's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
Company Info
ARIDIS PHARMACEUTICALS INC
983 University Avenue, Bldg. B
Los Gatos CALIFORNIA 95032 US
CEO: Vu Truong
Employees: 37
Company Website: https://aridispharma.com
Phone: 14083851742.0
ARIDIS PHARMACEUTICALS INC / ARDS FAQ
What is the stock price of ARIDIS PHARMACEUTICALS INC today?
The current stock price of ARDS is 0.3101 USD. The price increased by 17.91% in the last trading session.
What is the ticker symbol for ARIDIS PHARMACEUTICALS INC stock?
The exchange symbol of ARIDIS PHARMACEUTICALS INC is ARDS and it is listed on the Nasdaq exchange.
On which exchange is ARDS stock listed?
ARDS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARIDIS PHARMACEUTICALS INC stock?
8 analysts have analysed ARDS and the average price target is 10.2 USD. This implies a price increase of 3189.26% is expected in the next year compared to the current price of 0.3101. Check the ARIDIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARIDIS PHARMACEUTICALS INC worth?
ARIDIS PHARMACEUTICALS INC (ARDS) has a market capitalization of 11.23M USD. This makes ARDS a Nano Cap stock.
How many employees does ARIDIS PHARMACEUTICALS INC have?
ARIDIS PHARMACEUTICALS INC (ARDS) currently has 37 employees.
What are the support and resistance levels for ARIDIS PHARMACEUTICALS INC (ARDS) stock?
ARIDIS PHARMACEUTICALS INC (ARDS) has a support level at 0.23 and a resistance level at 0.32. Check the full technical report for a detailed analysis of ARDS support and resistance levels.
Is ARIDIS PHARMACEUTICALS INC (ARDS) expected to grow?
The Revenue of ARIDIS PHARMACEUTICALS INC (ARDS) is expected to grow by 1609.12% in the next year. Check the estimates tab for more information on the ARDS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARIDIS PHARMACEUTICALS INC (ARDS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARDS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARDS, evaluating the profitability, health, valuation and growth aspects
- ARIDIS PHARMACEUTICALS INC (ARDS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARIDIS PHARMACEUTICALS INC (ARDS) Sales and EPS estimates to see what analysts future expectations are.
- ARIDIS PHARMACEUTICALS INC (ARDS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARIDIS PHARMACEUTICALS INC (ARDS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARIDIS PHARMACEUTICALS INC (ARDS) Stock Chart to make your own analysis
- ARIDIS PHARMACEUTICALS INC (ARDS) Latest news and press-releases to stay up to date.
Does ARIDIS PHARMACEUTICALS INC (ARDS) stock pay dividends?
ARDS does not pay a dividend.
When does ARIDIS PHARMACEUTICALS INC (ARDS) report earnings?
ARIDIS PHARMACEUTICALS INC (ARDS) will report earnings on 2023-08-14, after the market close.
What is the Price/Earnings (PE) ratio of ARIDIS PHARMACEUTICALS INC (ARDS)?
ARIDIS PHARMACEUTICALS INC (ARDS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).
What is the Short Interest ratio of ARIDIS PHARMACEUTICALS INC (ARDS) stock?
The outstanding short interest for ARIDIS PHARMACEUTICALS INC (ARDS) is 0.01% of its float. Check the ownership tab for more information on the ARDS short interest.
ARDS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ARDS. When comparing the yearly performance of all stocks, ARDS is a bad performer in the overall market: 84.97% of all stocks are doing better.
ARDS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARDS. Both the profitability and financial health of ARDS have multiple concerns.
ARDS Financial Highlights
Over the last trailing twelve months ARDS reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 53.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARDS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ARDS. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 71.9% and a revenue growth 1609.12% for ARDS